TCRX

TScan Therapeutics, Inc. [TCRX] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

TCRX Stock Summary

Top 10 Correlated ETFs

TCRX

Top 10 Correlated Stocks

TCRX

In the News

TCRX Financial details

Company Rating
-
Market Cap
337.94M
Income
-89.99M
Revenue
21.05M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
154
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-6.26
Forward P/E
-
PEG
2.09
P/S
18.53
P/B
3.31
P/C
-
P/FCF
-4.45
Quick Ratio
6.5
Current Ratio
4.68
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.92
EPS next Y
-
EPS next Q
-
EPS this Y
-50.36%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
85.52%
EPS Q/Q
-12.5%
-
-
-
-
SMA20
7.6%
SMA50
23.49%
SMA100
38.35%
Inst Own
-
Inst Trans
-
ROA
-31%
ROE
-66%
ROC
-0.35%
Gross Margin
100%
Oper. Margin
-656%
Profit Margin
-644%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.62-9.0
52W High
-80.44%
52W Low
+76%
RSI
46.01
Rel Volume
1.39
Avg Volume
164.23K
Volume
228.37K
Perf Week
-5.88%
Perf Month
1.15%
Perf Quarter
5.39%
Perf Half Y
-2.22%
-
-
-
-
Beta
0.862
-
-
Volatility
0.05%, 0.09%
Prev Close
-4.86%
Price
1.76
Change
-4.86%

Something similar

Top by Market Cap
ABEC.DE
LLY.SW
ABEA.DE
MSF.DE
APC.DE
Top Correlated ETFs
ZIG
TMFS
FNK
KRE
KBE
Top Correlated Stocks
COMP
AVNT
VAC
RNST
DTIL
Similar Market Cap
MOZ.TO
ADRA
BCD
AMS.L
NEXAM.ST

Company Profile

Healthcare Biotechnology
  • Volume Average 164.23K
  • Market Capitalization 337.94M
  • Employee 154
  • CEO Dr. Gavin MacBeath Ph.D.
  • Headquarters Waltham,MA,US
  • IPO Date 2021-07-16
  • Website https://www.tscan.com

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.